GlassScriptPhysician profile
Aditya Vikram Jain
NPI 1013398692
$1,371.42
in general payments reported to CMS, 2019-2025
16 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2022: $283 · 2023: $150 · 2024: $552 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $459.39 | 2022-2024 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $205.60 | 2023-2025 | |
| Amgen INC. | $160.46 | 2019-2025 | Krystexxa, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.89 | 2024 | Jardiance |
| Fresenius USA Marketing, INC. | $77.16 | 2022-2024 | Crit-Line, 2008t Bluestar Hemodialysis Machine, Korsuva |
| Vifor Pharma, INC. | $66.12 | 2022-2023 | Korsuva, Veltassa |
| Ardelyx, INC. | $43.41 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $40.30 | 2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $38.44 | 2022-2023 | Benlysta |
| Calliditas Therapeutics US INC. | $32.38 | 2025 | Tarpeyo |
| Travere Therapeutics, INC. | $28.05 | 2025 | |
| Mallinckrodt Hospital Products INC. | $26.64 | 2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $23.32 | 2024 | |
| Akebia Therapeutics INC | $21.11 | 2022 | |
| Aurinia Pharma U.S., INC. | $20.39 | 2024 | Lupkynis |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $15.76 | 2023 | Jynarque |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditya Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.